Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: J Clin Virol. 2015 Nov 18;76(Suppl 1):S62–S68. doi: 10.1016/j.jcv.2015.11.020

Table 1.

Characteristics of currently available HPV vaccines

Bivalent Quandrivalent Nonavalent
Brand name CERVARIX GARDASIL®, SILGARD GARDASIL®9
Manufacturer GlaxoSmithKline Biologicals, Rixensart, Belgium MERCK & CO., INC., Whitehouse station, NJ, USA MERCK & CO., INC., Whitehouse station, NJ, USA
Approval year, FDA HPV types 2009

16, 18		 2006
6, 11
16, 18		 2014
6, 11
16, 18
31, 33, 45, 52, 58
Target population Females aged 9–25 years Females aged 9–26 years
Males aged 9–26 years		 Females aged 9–26 years
Males aged 9–15 years
Dose and schedule Three doses, 0.5ml/dose at 0, 1, and 6 months Three doses, 0.5ml/dose at 0, 2, and 6 months Three doses, 0.5ml/dose at 0, 2, and 6 months

FDA: Food and Drug Administration